Spectrum Pharmaceuticals

.

FDA OK’s Spectrum Cancer Drug for Wider Use

Spectrum Pharmaceuticals

An Irvine drug maker, Spectrum Pharmaceuticals Inc., has said that it got regulatory approval for an expanded use of a cancer drug.

Spectrum said that the FDA approved Zevalin as an early treatment for a blood cancer, in patients with non-Hodgkin's lymphoma. The drug was used previously on patients whose tumors did not respond to other treatments.

Spectrum Pharmaceuticals inks 50:50 JV pact with Cell Therapeutics

Spectrum Pharmaceuticals inks 50:50 JV pact with Cell Therapeutics Spectrum Pharmaceuticals and Cell Therapeutics have entered into an agreement to form a 50:50 owned joint venture, RIT Oncology, to commercialize and develop Zevalin in the United States.

Latest News

Target's Holiday Season Sales Expected to Fetch Good Results
Uber’s New York Office Executive Investigated for Spying on Journalist
China’s Factory Gauge in November Dropped to a Six Month Low
Fed Debate Continues Regarding Tightening of Pace After the First Rate Increase
San Diego Gives Green Signal to Landmark Water Recycling Plans
NHTSA Urges Takata to Recall Faulty Air-Bags Nationwide
Home Prices in Beijing Drop for the First Time in Two Years Following an Economi
Urban Outfitters Miss Analyst Expectations in Third Quarter Earnings
Friendly $34.6 Billion Merger Deal Between Halliburton and Baker Hughes after Ne
Abe Expected to Announce Tax Hike Delay and a Snap Poll in Japan
Toray’s Shares Jump to Highest Since 2008 with	Boeing’s 1 Trillion Yen Order
Ignition Compensation Deadline Extended by GM to January 31
Syndicate content